Expression and mutational analysis of Nm23-H1 in liver metastases of colorectal cancer.

Tekijä Heide, I., Thiede, C., Poppe, K., de Kant, E., Huhn, D., Rochlitz, C.
Julkaistu 1994

Treatment of malignant obstruction of the superior vena cava with the self-expanding Wallstent.

Tekijä Stock, K. W., Jacob, A. L., Proske, M., Bolliger, C. T., Rochlitz, C., Steinbrich, W.
Julkaistu 1995

Specific immunotherapy of MUC1-positive adenocarcinomas with a recombinant vaccinia virus expressing MUC1 and IL-2

Tekijä Bizouarne, N, Squiban, P, Acres, B, Balloul, JM, Ohresser, MA, Figlin, R, Belldegrun, A, Herrman, R, Rochlitz, C
Julkaistu 2001

Molecular alterations in a patient with Turcot's syndrome.

Tekijä Rochlitz, C. F., Heide, I., de Kant, E., Neubauer, A., Schmidt, C. A., Neuhaus, P., Huhn, D., Herrmann, R.
Julkaistu 1993

SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer

Tekijä Boulay, J-L, Mild, G, Lowy, A, Reuter, J, Lagrange, M, Terracciano, L, Laffer, U, Herrmann, R, Rochlitz, C
Julkaistu 2002

SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer

Tekijä Boulay, J-L, Mild, G, Lowy, A, Reuter, J, Lagrange, M, Terracciano, L, Laffer, U, Herrmann, R, Rochlitz, C
Julkaistu 2003

Infrequent mutation of the tumour-suppressor gene Smad4 in early-stage colorectal cancer

Tekijä Mamot, C, Mild, G, Reuter, J, Laffer, U, Metzger, U, Terracciano, L, Boulay, J-L, Herrmann, R, Rochlitz, C
Julkaistu 2003

Focusing on cancer patients' intentions to use psychooncological support: A longitudinal, mixed‐methods study

Tekijä Tondorf, T., Grossert, A., Rothschild, S.I., Koller, M.T., Rochlitz, C., Kiss, A., Schaefert, R., Meinlschmidt, G., Hunziker, S., Zwahlen, D.
Julkaisussa Psychooncology (2018)

BRCA1 mutations in a selected series of breast/ovarian cancer patients.

Tekijä Garvin, A M, Spycher, M, Häner, M, Torhorst, J, Müller, H, Herrmann, R, Rochlitz, C, Weber, W, Scott, R J
Julkaistu 1996

Capecitabine in hormone-resistant metastatic prostatic carcinoma – a phase II trial

Tekijä Morant, R, Bernhard, J, Dietrich, D, Gillessen, S, Bonomo, M, Borner, M, Bauer, J, Cerny, T, Rochlitz, C, Wernli, M, Gschwend, A, Hanselmann, S, Hering, F, Schmid, H-P
Julkaistu 2004

Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings

Tekijä Tartour, E, Mehtali, M, Sastre-Garau, X, Joyeux, I, Mathiot, C, Pleau, J M, Squiban, P, Rochlitz, C, Courtney, M, Jantscheff, P, Herrmann, R, Pouillart, P, Fridman, W H, Dorval, T
Julkaistu 2000